))
KRAS Inhibition in NSCLC: When, How, and Why?
Manage episode 407462010 series 3560609
Content provided by Jacqueline Stone and Oncololgy News Central. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jacqueline Stone and Oncololgy News Central or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Melissa Johnson, MD,a medical oncologist with Tennessee Oncology and Director of Lung Cancer Research at Sarah Cannon Research Institute in Nashville,joins host Robert Figlin, MD, Steven Spielberg Family Chair in HematologyOncologyat Cedars-Sinai Cancer, to talk about KRAS G12C inhibition in non-small cell lung cancer (NSCLC)treatment. She talks about how she uses sotorasib (Lumakras), which is U.S. Food and Drug Administration (FDA)approved for second-line treatment, why plasma-based genetic testing is so important, and how she explains to patients that even though she can’t start them off with this drug in the first-line, having it in reserve is a good plan.
…
continue reading
124 episoade
Distribuie
